# A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

> **NCT01987479** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 150 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Non-Biologic DMARDs
- **DRUG:** Tocilizumab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01987479
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-30
- **Primary completion:** 2016-05-26
- **Final completion:** 2016-05-26
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01987479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01987479, "A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01987479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*